Taysha Gene Therapies 

Taysha Gene Therapies 

Yahoo Finance • 6 days ago

5 Best Biotech Stocks Under $10 to Buy

In this article we will present the 5 best biotech stocks under $10 to buy. For an expanded list, please see the 10 Best Biotech Stocks Under $10 to Buy. Biotechnology stocks have delivered strong gains in 2026, supported by encouraging c... Full story

Yahoo Finance • 3 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Nebius Group N.V. (NBIS [https://seekingalpha.com/symbol/NBIS]) * Tencent Holdings Limited (TCEHY [https://seekingalpha.com/symbol/TCEHY]) * Brinker International (EAT... Full story

Yahoo Finance • 3 months ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monoge... Full story

Yahoo Finance • 3 months ago

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

CAMBRIDGE, Mass. and DALLAS and TAMPA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc., (Nasdaq: TSHA) (Taysha), a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene the... Full story

Yahoo Finance • 4 months ago

Taysha Gene Therapies (TSHA) is One of The Most Affordable Biotech Names to Invest In

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the 10 affordable biotech stocks to buy right now. On June 24, Taysha Gene Therapies Inc. (NASDAQ:TSHA) disclosed the pricing of an underwritten public offering of 32.5 million of its com... Full story

Yahoo Finance • 4 months ago

Biggest stock movers Thursday: AI chip stocks, WEN, SPRY, and more

[Analyzing Business Performance Through Data Analytics] U.S. stock futures edged higher on Thursday, supported by a stellar earnings report from Micron Technology, as markets turned their focus to the release of key May inflation data for... Full story

Yahoo Finance • 4 months ago

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monoge... Full story

Yahoo Finance • 6 months ago

Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the best small cap stocks to buy for 10x potential. Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced financial results for fiscal Q1 2026 on May 6, reporting that it reaffirmed U.S. Fo... Full story

Yahoo Finance • 7 months ago

Taysha Gene Therapies (TSHA) Stock Price Surges 343.45% From Year Ago Levels

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock is up 343.45% from its price a year ago and 22.48% year-to-date. On April 15, Needham reiterated its buy rating fo... Full story

Yahoo Finance • 7 months ago

This is Why Taysha Gene Therapies, Inc. (TSHA) is one of the Best Healthcare Penny Stocks to Buy

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best healthcare penny stocks to buy according to hedge funds. On April 6, Canaccord reiterated its Buy rating on Taysha Gene Therapies Inc. (NASDAQ:TSHA) and raised its price target to... Full story

Yahoo Finance • 8 months ago

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story

Yahoo Finance • 8 months ago

Taysha Gene Therapies Q4 Earnings Call Highlights

Taysha Gene Therapies logo Key Points Regulatory and trial progress: TSHA-102 received FDA Breakthrough Therapy designation, Taysha has initiated the REVEAL pivotal trial and obtained clearance for the safety-focused ASPIRE study, with F... Full story

Yahoo Finance • 8 months ago

Taysha Gene Therapies GAAP EPS of -$0.34 beats by $0.02, revenue of $9.77M beats by $3.47M

* Taysha Gene Therapies press release [https://seekingalpha.com/pr/20444333-taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update] (TSHA [https://seekingalpha.com/symbol/TSHA]): FY GAAP EPS of -$0.3... Full story

Yahoo Finance • 8 months ago

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to... Full story

Yahoo Finance • 8 months ago

Taysha Gene Therapies FY 2025 Earnings Preview

* Taysha Gene Therapies (TSHA [https://seekingalpha.com/symbol/TSHA]) is scheduled to announce FY earnings results on Thursday, March 19th, before market open. The consensus EPS Estimate is -$0.34 [https://seekingalpha.com/symbol/TSHA/ea... Full story

Yahoo Finance • 9 months ago

Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Taysha Gene Therapies, Inc. is placed sixth on our list of best biotech stocks under $20. TheFly reported on January 5 that Wells Fargo raised its price targe... Full story

Yahoo Finance • 12 months ago

Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now?

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a must-buy penny stock to buy now. On November 13, Piper Sandler analyst Biren Amin reaffirmed his Buy rating on Taysha Gene Therapies, assigning a $9 price target. On November 5, Truist Financia... Full story

Yahoo Finance • last year

Taysha outlines accelerated BLA timeline for TSHA-102 with FDA Breakthrough Therapy designation and full global rights

Earnings Call Insights: Taysha Gene Therapies (TSHA) Q3 2025 MANAGEMENT VIEW * CEO Sean Nolan stated, “The recent regulatory clarity and progress we've achieved, which was enabled by the strength of our REVEAL Part A data set, rigorous... Full story

Yahoo Finance • last year

Taysha Gene Therapies regains full rights to TSHA-102

designer491/iStock via Getty Images * Taysha Gene Therapies (NASDAQ:TSHA [https://seekingalpha.com/symbol/TSHA]) has announced that it has regained complete rights to its leading program, TSHA-102, which is currently being evaluated for... Full story

Yahoo Finance • last year

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has... Full story